HC Wainwright Predicts Lower Earnings for Lexeo Therapeutics

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities research analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Lexeo Therapeutics in a report issued on Thursday, November 14th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($3.22) per share for the year, down from their previous estimate of ($2.75). HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.00) EPS and FY2025 earnings at ($3.84) EPS.

Other research analysts also recently issued research reports about the stock. Leerink Partners dropped their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Chardan Capital upped their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $22.71.

Lexeo Therapeutics Trading Up 0.3 %

Shares of Lexeo Therapeutics stock opened at $6.02 on Monday. The company has a market capitalization of $199.08 million and a P/E ratio of -1.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The company has a fifty day moving average of $8.91 and a 200 day moving average of $12.18. Lexeo Therapeutics has a fifty-two week low of $5.80 and a fifty-two week high of $22.33.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the transaction, the chief executive officer now owns 120,695 shares of the company’s stock, valued at $977,629.50. This represents a 3.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 12,500 shares of company stock valued at $113,300 in the last 90 days. Insiders own 4.50% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

Several hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC raised its position in shares of Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after buying an additional 599,203 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Lexeo Therapeutics during the 3rd quarter valued at about $11,307,000. Vestal Point Capital LP raised its position in shares of Lexeo Therapeutics by 1.2% during the 3rd quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after buying an additional 10,000 shares in the last quarter. Artal Group S.A. raised its position in shares of Lexeo Therapeutics by 32.9% during the 1st quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock valued at $12,571,000 after buying an additional 198,281 shares in the last quarter. Finally, Verition Fund Management LLC raised its position in shares of Lexeo Therapeutics by 84.5% during the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after buying an additional 355,928 shares in the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.